<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02648698</url>
  </required_header>
  <id_info>
    <org_study_id>FuXingH</org_study_id>
    <nct_id>NCT02648698</nct_id>
  </id_info>
  <brief_title>RCT(Randomized Clinical Trial ) of Antibiotic Therapy in Chronic Endometritis</brief_title>
  <official_title>A Prospective, Randomized,Controlled Trial on the Effect of Antibiotic Therapy on Endometrial Response in Women With Chronic Endometritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fu Xing Hospital, Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fu Xing Hospital, Capital Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      120 cases with a diagnosis of chronic endometritis, confirmed by the presence of plasma cells
      in endometrial biopsy sample identified by immunohistochemical staining using CD138 antibody,
      have been recruited. The subjects have been randomly divided into two groups, the
      experimental group have been given antibiotic (Levofloxacin and Tinidazole for 14 days)
      treatment, the control group did not receive any antibiotic. Initially it was planned for
      women in the control group to take placebo,but the organization was difficult, so it was
      changed prior to the start of the study to an open label study. A repeat endometrial biopsy
      sample have been obtained 2-4 weeks after completion of the antibiotic therapy to assess the
      response to treatment. The conversion rate will be compared between the two groups
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be carried out at the Hysteroscopy centre of the Fuxing Hospital, Capital
      Medical University ,Beijing, China. A total of 120 women with chronic endometritis who
      fulfilled the following inclusion criteria will be recruited:

        1. CD138 immunohistochemical staining of endometrial specimen showed presence of one or
           more plasma cells per 10HPF which confirmed chronic endometritis, according to published
           criteria.

        2. women who were pre-menopausal.

        3. no evidence of endometrial hyperplasia or malignancy or structural uterine pathology.

        4. agreement to have a second endometrial biopsy ~4 weeks after the initial endometrial
           biopsy.

        5. written informed consent obtained

      Exclusion Criteria:

        1. women who received steroid hormone therapy within one month of recruitment.

        2. allergy or suspected allergy to the chosen antibiotic therapy.

        3. women who developed any concurrent infection and received any antibiotic therapy during
           the period of study other than the one prescribed according to the study protocol.

      Power calculation: Assuming that the spontaneous CD138 conversion (from positive to negative
      ) rate is 25% and that the antibiotic therapy results in 60% conversion rate, the total
      number of subjects required in each arm of the RCT will be 37, accepting a Type I error of
      0.05 and a Type II error of 0.1, and assuming a drop-out rate of 20%, 45 subjects will need
      to be recruited into each arm. Hence, a total of 90 subjects who fulfilled the inclusion
      criteria will be required.

      Recruitment: Women have been recruited form the day case hysteroscopy unit of the
      Hysteroscopy center, Fuxing Hospital, Beijing, China. The Hysteroscopy center currently
      carries out ~600 day case hysteroscopy per month. In all cases, endometrial biopsy specimen
      will be obtained at the time of hysteroscopy for histological evaluation. Since 2013, all
      endometrial specimens have been routinely examined with the used of CD138 antibody to
      establish if there is evidence of chronic endometritis, in addition to routine
      histopathological examination. Previous audit showed that ~15% of subjects had positive
      staining for CD138 cells.We recruited the initial 132 subjects according to the inclusion and
      exclusion criteria succesfully from July 2016 to December 2018.

      Randomization:Women who had histological confirmation of CE in an endometrial biopsy specimen
      and who fulfilled the inclusion criteria were randomized into the antibiotic group and
      control group in a 1:1 ratio using a computer-generated randomization list and sealed opaque
      envelopes prepared by the first author. The patients were not blinded to the antibiotic
      treatment. The pathologist who performed the histological evaluation was blinded to the
      treatment.

      Antibiotic therapy: Women who were randomized to the treatment group were given oral
      Levofloxacin and Tinidazole daily for 14 days.

      Women who were randomized to the control group did not receive any antibiotic. Staff
      Pharmacist dispense medication.

      Consent: written informed consent will be obtained

      Repeat endometrial biopsy &amp; histological evaluation: The repeat endometrial biopsy will be
      performed after completion of the the antibiotic therapy. Immunohistochemical study using
      CD138 antibody will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2016</start_date>
  <completion_date type="Actual">December 15, 2018</completion_date>
  <primary_completion_date type="Actual">December 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Conversion Rate of CE (From Positive to Negative)</measure>
    <time_frame>1-6 months</time_frame>
    <description>Subjects in antibiotic group underwent a second-look hysteroscopy and repeat endometrial biopsy for histopathological CD138 immunohistochemical examination 2-4 weeks after completion of antibiotic treatment and in the follicular phase of the following menstrual cycle. Subjects in control group underwent a second-look hysteroscopy and repeat endometrial biopsy for histopathological CD138 immunohistochemical examination ~4 weeks after recruitment in the follicular phase of the following menstrual cycle.
The biopsies were graded as &quot;negative&quot; for CE if there was less than one plasma cell identified per 10 high-power fields (HPFs) and &quot;positive&quot; when there was one or more plasma cell identified per 10 HPFs.
To compare the cure rate (From positive to negative) of CE in women who received antibiotic therapy (treatment group) with the spontaneous cure rate in those who did not receive antibiotic therapy (control group),</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Chronic Endometritis</condition>
  <arm_group>
    <arm_group_label>Antibiotic group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group received antibiotic therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group did not receive antibiotic therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics</intervention_name>
    <description>Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group</description>
    <arm_group_label>Antibiotic group</arm_group_label>
    <other_name>Levofloxacin and Tinidazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. CD138 immunohistochemical staining of endometrial specimen showed presence of one or
             more plasma cells per 10HPF which confirmed chronic endometritis, according to
             published criteria.

          2. women who were pre-menopausal.

          3. no evidence of endometrial hyperplasia or malignancy or structural uterine pathology.

          4. agreement to have a second endometrial biopsy ~4 weeks after the initial endometrial
             biopsy.

          5. written informed consent obtained

        Exclusion Criteria:

          1. women who received steroid hormone therapy within one month of recruitment.

          2. allergy or suspected allergy to the chosen antibiotic therapy.

          3. women who developed any concurrent infection and received any antibiotic therapy
             during the period of study other than the one prescribed according to the study
             protocol.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongmei Song, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>FuXing Hospital,Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Enlan Xia, Master</last_name>
    <role>Study Director</role>
    <affiliation>FuXing Hospital,Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tinchiu Li, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>FuXing Hospital,Capital Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaoxia Peng, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Capital Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FuXing Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/26207958</url>
    <description>2015</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/24462055</url>
    <description>2014</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/24177713</url>
    <description>2013 Oct 31</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/21030015</url>
    <description>2011 Mar</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Routine+syndecan-1+immunohistochemistry+aids+in+the+diagnosis+of+chronic+endometritis</url>
    <description>2004 Sep</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/23440678</url>
    <description>2012 Jul</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=Immunohistochemistrical+and+clinicopathological+characterization+of+chronic+endometritis</url>
    <description>2011 Jul 12</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/25385744</url>
    <description>2015 Feb</description>
  </link>
  <reference>
    <citation>McQueen DB, Bernardi LA, Stephenson MD. Chronic endometritis in women with recurrent early pregnancy loss and/or fetal demise. Fertil Steril. 2014 Apr;101(4):1026-30. doi: 10.1016/j.fertnstert.2013.12.031. Epub 2014 Jan 23.</citation>
    <PMID>24462055</PMID>
  </reference>
  <reference>
    <citation>Cicinelli E, Matteo M, Tinelli R, Pinto V, Marinaccio M, Indraccolo U, De Ziegler D, Resta L. Chronic endometritis due to common bacteria is prevalent in women with recurrent miscarriage as confirmed by improved pregnancy outcome after antibiotic treatment. Reprod Sci. 2014 May;21(5):640-7. doi: 10.1177/1933719113508817. Epub 2013 Oct 31.</citation>
    <PMID>24177713</PMID>
  </reference>
  <reference>
    <citation>Kitaya K. Prevalence of chronic endometritis in recurrent miscarriages. Fertil Steril. 2011 Mar 1;95(3):1156-8. doi: 10.1016/j.fertnstert.2010.09.061. Epub 2010 Oct 28.</citation>
    <PMID>21030015</PMID>
  </reference>
  <reference>
    <citation>Bayer-Garner IB, Nickell JA, Korourian S. Routine syndecan-1 immunohistochemistry aids in the diagnosis of chronic endometritis. Arch Pathol Lab Med. 2004 Sep;128(9):1000-3.</citation>
    <PMID>15335255</PMID>
  </reference>
  <reference>
    <citation>Kannar V, Lingaiah HK, Sunita V. Evaluation of endometrium for chronic endometritis by using syndecan-1 in abnormal uterine bleeding. J Lab Physicians. 2012 Jul;4(2):69-73. doi: 10.4103/0974-2727.105584.</citation>
    <PMID>23440678</PMID>
  </reference>
  <reference>
    <citation>Kitaya K, Yasuo T. Immunohistochemistrical and clinicopathological characterization of chronic endometritis. Am J Reprod Immunol. 2011 Nov;66(5):410-5. doi: 10.1111/j.1600-0897.2011.01051.x. Epub 2011 Jul 12.</citation>
    <PMID>21749546</PMID>
  </reference>
  <reference>
    <citation>Cicinelli E, Matteo M, Tinelli R, Lepera A, Alfonso R, Indraccolo U, Marrocchella S, Greco P, Resta L. Prevalence of chronic endometritis in repeated unexplained implantation failure and the IVF success rate after antibiotic therapy. Hum Reprod. 2015 Feb;30(2):323-30. doi: 10.1093/humrep/deu292. Epub 2014 Nov 10.</citation>
    <PMID>25385744</PMID>
  </reference>
  <results_reference>
    <citation>McQueen DB, Perfetto CO, Hazard FK, Lathi RB. Pregnancy outcomes in women with chronic endometritis and recurrent pregnancy loss. Fertil Steril. 2015 Oct;104(4):927-931. doi: 10.1016/j.fertnstert.2015.06.044. Epub 2015 Jul 21.</citation>
    <PMID>26207958</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>January 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <results_first_submitted>February 26, 2020</results_first_submitted>
  <results_first_submitted_qc>May 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2020</results_first_posted>
  <last_update_submitted>May 30, 2020</last_update_submitted>
  <last_update_submitted_qc>May 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fu Xing Hospital, Capital Medical University</investigator_affiliation>
    <investigator_full_name>Song Dongmei</investigator_full_name>
    <investigator_title>Hysteroscopy Center</investigator_title>
  </responsible_party>
  <keyword>chronic endometritis</keyword>
  <keyword>CD138</keyword>
  <keyword>antibiotic</keyword>
  <keyword>conversion rate.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Tinidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT02648698/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 120 subjects were assessed for eligibility. All of the 120 subjects were enrolled and randomized into the antibiotic group and the control group on a 1:1 ratio.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Antibiotic Group</title>
          <description>This group received antibiotic therapy
Antibiotics: Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>This group did not receive antibiotic therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Antibiotic Group</title>
          <description>This group received antibiotic therapy
Antibiotics: Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>This group did not receive antibiotic therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.86" spread="4.7"/>
                    <measurement group_id="B2" value="31.93" spread="4.8"/>
                    <measurement group_id="B3" value="31.89" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.91" spread="3.4"/>
                    <measurement group_id="B2" value="22.28" spread="3.5"/>
                    <measurement group_id="B3" value="22.61" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parity</title>
          <units>events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.15" spread="0.9"/>
                    <measurement group_id="B2" value="2.15" spread="0.9"/>
                    <measurement group_id="B3" value="2.15" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Miscarriage</title>
          <units>events</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.59" spread="1.0"/>
                    <measurement group_id="B2" value="1.93" spread="1.0"/>
                    <measurement group_id="B3" value="1.75" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Conversion Rate of CE (From Positive to Negative)</title>
        <description>Subjects in antibiotic group underwent a second-look hysteroscopy and repeat endometrial biopsy for histopathological CD138 immunohistochemical examination 2-4 weeks after completion of antibiotic treatment and in the follicular phase of the following menstrual cycle. Subjects in control group underwent a second-look hysteroscopy and repeat endometrial biopsy for histopathological CD138 immunohistochemical examination ~4 weeks after recruitment in the follicular phase of the following menstrual cycle.
The biopsies were graded as &quot;negative&quot; for CE if there was less than one plasma cell identified per 10 high-power fields (HPFs) and &quot;positive&quot; when there was one or more plasma cell identified per 10 HPFs.
To compare the cure rate (From positive to negative) of CE in women who received antibiotic therapy (treatment group) with the spontaneous cure rate in those who did not receive antibiotic therapy (control group),</description>
        <time_frame>1-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antibiotic Group</title>
            <description>This group received antibiotic therapy
Women who were randomized to the treatment group were given oral Levofloxacin 500 mg and Tinidazole 1000 mg daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Women who were randomized to the control group did not receive any antibiotic.</description>
          </group>
        </group_list>
        <measure>
          <title>The Conversion Rate of CE (From Positive to Negative)</title>
          <description>Subjects in antibiotic group underwent a second-look hysteroscopy and repeat endometrial biopsy for histopathological CD138 immunohistochemical examination 2-4 weeks after completion of antibiotic treatment and in the follicular phase of the following menstrual cycle. Subjects in control group underwent a second-look hysteroscopy and repeat endometrial biopsy for histopathological CD138 immunohistochemical examination ~4 weeks after recruitment in the follicular phase of the following menstrual cycle.
The biopsies were graded as &quot;negative&quot; for CE if there was less than one plasma cell identified per 10 high-power fields (HPFs) and &quot;positive&quot; when there was one or more plasma cell identified per 10 HPFs.
To compare the cure rate (From positive to negative) of CE in women who received antibiotic therapy (treatment group) with the spontaneous cure rate in those who did not receive antibiotic therapy (control group),</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.8" lower_limit="82.2" upper_limit="97.5"/>
                    <measurement group_id="O2" value="12.7" lower_limit="3.9" upper_limit="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Antibiotic Group</title>
          <description>This group received antibiotic therapy
Antibiotics: Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>This group did not receive antibiotic therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A possible limitation of our study is that patients were not blinded to the antibiotic treatment. A further limitation is the cure rate based on a repeat of test used to make the diagnosis, instead of pregnancy, miscarriage or live birth.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Dongmei Song</name_or_title>
      <organization>Department of Hysteroscopic Centre, Fuxing Hospital, the Eighth Clinical Medical College, Capital Medical University, Beijing, China</organization>
      <phone>13651294056 ext 86</phone>
      <email>echosdm@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

